AIM: To study the relation between CYP1A1 Ile462Val polymorphism and colorectal cancer risk by meta-analysis. METHODS: A meta-analysis was performed to investigate the relation between CYP1A1 Ile462Val polymorphism and colorectal cancer risk by reviewing the related studies until September 2010. Data were extracted and analyzed. Crude odds ratio (OR) with 95% confidence interval (CI) was used to assess the strength of relation between CYP1A1 Ile462Val polymorphism and colorectal cancer risk. RESULTS: Thirteen published case-control studies including 5336 cases and 6226 controls were acquired. The pooled OR with 95% CI indicated that CYP1A1 Ile462Val polymorphism was significantly related with colorectal cancer risk (Val/Val vs Ile/Ile: OR = 1.47, 95% CI: 1.16-1.86, P = 0.002; dominant model: OR = 1.33, 95% CI: 1.01-1.75, P = 0.04; recessive model: OR = 1.49, 95% CI: 1.18-1.88, P = 0.0009). Subgroup ethnicity analysis showed that CYP1A1 Ile462Val polymorphism was also significantly related with colorectal cancer risk in Europeans (Ile/Val vs Ile/Ile: OR = 1.22, 95% CI: 1.05-1.42, P = 0.008; dominant model: OR = 1.24, 95% CI: 1.07-1.43, P = 0.004) and Asians (Val/Val vs Ile/Ile: OR = 1.40, 95% CI: 1.07-1.82, P = 0.01; recessive model: OR = 1.46, 95% CI: 1.12-1.89, P = 0.005). CONCLUSION: CYP1A1 Ile462Val may be an increased risk factor for colorectal cancer.
AIM: To study the relation between CYP1A1Ile462Val polymorphism and colorectal cancer risk by meta-analysis. METHODS: A meta-analysis was performed to investigate the relation between CYP1A1Ile462Val polymorphism and colorectal cancer risk by reviewing the related studies until September 2010. Data were extracted and analyzed. Crude odds ratio (OR) with 95% confidence interval (CI) was used to assess the strength of relation between CYP1A1Ile462Val polymorphism and colorectal cancer risk. RESULTS: Thirteen published case-control studies including 5336 cases and 6226 controls were acquired. The pooled OR with 95% CI indicated that CYP1A1Ile462Val polymorphism was significantly related with colorectal cancer risk (Val/Val vs Ile/Ile: OR = 1.47, 95% CI: 1.16-1.86, P = 0.002; dominant model: OR = 1.33, 95% CI: 1.01-1.75, P = 0.04; recessive model: OR = 1.49, 95% CI: 1.18-1.88, P = 0.0009). Subgroup ethnicity analysis showed that CYP1A1Ile462Val polymorphism was also significantly related with colorectal cancer risk in Europeans (Ile/Val vs Ile/Ile: OR = 1.22, 95% CI: 1.05-1.42, P = 0.008; dominant model: OR = 1.24, 95% CI: 1.07-1.43, P = 0.004) and Asians (Val/Val vs Ile/Ile: OR = 1.40, 95% CI: 1.07-1.82, P = 0.01; recessive model: OR = 1.46, 95% CI: 1.12-1.89, P = 0.005). CONCLUSION:CYP1A1Ile462Val may be an increased risk factor for colorectal cancer.
Authors: Anna Abulí; Xavier Bessa; Juan Ramón González; Clara Ruiz-Ponte; Alejandro Cáceres; Jenifer Muñoz; Victoria Gonzalo; Francesc Balaguer; Ceres Fernández-Rozadilla; Dolors González; Luisa de Castro; Juan Clofent; Luís Bujanda; Joaquín Cubiella; Josep M A Reñé; Juan Diego Morillas; Angel Lanas; Joaquim Rigau; Ana M A García; Mercedes Latorre; Joan Saló; Fernando Fernández Bañares; Lídia Argüello; Elena Peña; Angels Vilella; Sabino Riestra; Ramiro Carreño; Artemio Paya; Cristina Alenda; Rosa M Xicola; Brian J Doyle; Rodrigo Jover; Xavier Llor; Angel Carracedo; Antoni Castells; Sergi Castellví-Bel; Montserrat Andreu Journal: Gastroenterology Date: 2010-06-02 Impact factor: 22.682
Authors: Wen-Lei Zhuo; Yun-Song Zhang; Yan Wang; Xian-Lu Zhuo; Bo Zhu; Lei Cai; Zheng-Tang Chen Journal: Arch Med Res Date: 2009-02-25 Impact factor: 2.235